NCT06128837View on ClinicalTrials.gov

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

686

Participants

Timeline

Start Date

March 3, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

October 31, 2028

Conditions
Relapsed Small Cell Lung Cancer
Interventions
DRUG

Irinotecan hydrochloride liposome Injection

Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk

DRUG

Topotecan

Topotecan 1.2 mg/m² intravenously Days 1-5 q3w

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY